灵猫方联合恩替卡韦治疗慢性乙型肝炎临床研究

目的：探讨灵猫方联合恩替卡韦治疗慢性乙型肝炎（1×ULN≤ALT≤2×ULN）的临床疗效。方法：采用随机、双盲、安慰剂对照的方法,将56例患者分为治疗组28例和对照组28例。治疗组给予灵猫方联合恩替卡韦治疗,对照组给予安慰剂联合恩替卡韦治疗,疗程为12个月。观察两组患者的临床疗效及血清HBV-DNA、HBeAg、HBsAg水平的变化。结果：治疗后,治疗组和对照组的总有效率分别为92.86%和89.29%,两组比较差异无统计学意义（P〉0.05）;治疗组患者的HBV-DNA、HBsAg、HBeAg下降幅度明显大于对照组（P〈0.05）。结论：灵猫方联合恩替卡韦治疗慢性乙型肝炎（1×ULN≤ALT≤2×ULN）,在抑制乙肝病毒复制,降低HBsAg、HBeAg的表达方面优于单用恩替卡韦。

Clinical Study on "Lingmao Formula" with Entecavir in Treating Chronic Hepatitis B

Objective ： To explore the efficacy of ＂Lingmao Formula＂ with entecavir in treating chronic hepatitis B. Methods ： A randomized, double-blind and placebo-controlled trial was carried out. Fifty-six patients with chronic hepatitis B were divided into treatment group and control group, with 28 cases in each group. The treatment group was treated with ＂Lingmao Formula＂ with entecavir and the control group was treated with entecavir with a course of twelve months. The clinical effects and the levels of HBV DNA, HBeAg and HBsAg were observed. Results： The total effective rates of treatment group and control group were 92.86% and 89.29% respectively, with no statistical difference between two groups （P 〉 0.05）. After treatment, the levels of HBV DNA, HBeAg and HBsAg were decreased in treatment group more obviously than those in control group （ P 〈 0.05 ）. Conclusion： For chronic hepatitis B （1×ULN≤ALT≤2×ULN） patients, ＂Lingmao Formula＂ with entecavir is more efficient than entecavir alone in the aspects of inhibiting HBV and decreasing the expressions of HBeAg and HBsAg.